NASDAQ · AMLX
Healthcare · Biotechnology
$33.15
Down-$0.49 (-1.46%)
Updated Sep 16, 2026, 11:24 AM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
AMLX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning AMLX.
AMLX research
Company profile and research snapshot.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 27, 2026 | Guggenheim | Buy | — |
| Aug 19, 2026 | Mizuho | Outperform | — |
| Aug 19, 2026 | Guggenheim | Buy | — |
| Aug 19, 2026 | Baird | Outperform | — |
| Aug 18, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 10, 2026
Phase 3 sunRIZE miss in congenital hyperinsulinism hurts FDA odds; limited upside and high cash burn signal dilution risk. Click for more on RZLT stock.
Yahoo · Sep 9, 2026
FRAMINGHAM, Mass., September 09, 2026--Tortugas Neuroscience ("Tortugas"), a clinical-stage central nervous system (CNS)-focused biotech company developing medicines with clinically validated mechanisms of action in indications with both substantial patient populations and high unmet need, today announced the appointment of Jim Frates to its Board of Directors and as Chair of the Audit Committee. A highly experienced biopharmaceutical leader who has served as chief financial officer (CFO) for mu
Yahoo · Sep 8, 2026
CAMBRIDGE, Mass., September 08, 2026--Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
Yahoo · Sep 1, 2026
Amylyx looks promising, but a pullback would improve the opportunity.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AMLX.
